Table 4.
Senescent HPMCs | A2780 | OVCAR-3 | SKOV-3 | ||||
---|---|---|---|---|---|---|---|
HGF | VEGF | CXCL1 | CXCL8 | CXCL1 | CXCL8 | VEGF | |
IL-6 | P < 0.04 r = 0.541 |
P < 0.05 r = 0.621 |
P < 0.02 r = 0.744 |
P < 0.04 r = 0.641 |
P < 0.04 r = 0.523 |
P < 0.05 r = 0.671 |
P < 0.05 r = 0.473 |
TGF-β1 | P < 0.02 r = 0.827 |
P < 0.05 r = 0.635 |
P < 0.05 r = 0.732 |
P < 0.03 r = 0.742 |
P < 0.02 r = 0.826 |
P < 0.05 r = 0.463 |
P < 0.04 r = 0.632 |
Ovarian cancer cells were exposed to CM obtained from senescent HPMCs for 24 h. Afterwards, the media were removed, the cells were washed and then subjected to serum-free medium (for 24 h) to generate autologous CM. Concentrations of IL-6 and TGF-β1 in the CM from senescent HPMCs were correlated with concentrations of HGF, VEGF, CXCL1, and CXCL8 quantified in cancer cell-derived CM using the Spearman test. The results derive from experiments performed with CM produced by HPMCs from 22 different donors